04 August 2017 : Original article
Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection
DOI: 10.12659/AOT.903499
Ann Transplant 2017; 22:468-474
HTML version available soon